Subarachnoid hemorrhage continues to carry a high burden of mortality and morbidity in man. To facilitate further research into the condition and its pathophysiology, a pre-chiasmatic, single injection model is presented.
Despite advances in treatment over the last decades, subarachnoid hemorrhage (SAH) continues to carry a high burden of morbidity and mortality, largely afflicting a fairly young population. Several animal models of SAH have been developed to investigate the pathophysiological mechanisms behind SAH and to test pharmacological interventions. The pre-chiasmatic, single injection model in the rat presented in this article is an experimental model of SAH with a predetermined blood volume. Briefly, the animal is anesthetized, intubated, and kept under mechanical ventilation. Temperature is regulated with a heating pad. A catheter is placed in the tail artery, enabling continuous blood pressure measurement as well as blood sampling. The atlantooccipital membrane is incised and a catheter for pressure recording is placed in the cisterna magna to enable intracerebral pressure measurement. This catheter can also be used for intrathecal therapeutic interventions. The rat is placed in a stereotaxic frame, a burr hole is drilled anteriorly to the bregma, and a catheter is inserted through the burr hole and placed just anterior to the optic chiasm. Autologous blood (0.3 mL) is withdrawn from the tail catheter and manually injected. This results in a rise of intracerebral pressure and a decrease of cerebral blood flow. The animal is kept sedated for 30 min and given subcutaneous saline and analgesics. The animal is extubated and returned to its cage. The pre-chiasmatic model has a high reproducibility rate and limited variation between animals due to the pre-determined blood volume. It mimics SAH in humans making it a relevant model for SAH research.
Non-traumatic subarachnoid hemorrhage (SAH) is a form of stroke, representing around 5% of all cases. The most common cause of non-traumatic SAH is the sudden rupture of an aneurysm (aSAH), which accounts for 85% of SAHs. Other causes include the rupture of an arterio-venous malformation, coagulopathies, and rupture of veins in perimesencephalic hemorrhage1. The incidence rate is 9 per 100,000 person-years with mortality around one in three and another third requiring the support of daily living following SAH2,3.
Following initial stabilization and diagnosis confirmation, treatment depends on the severity of the hemorrhage. The most severely afflicted patients will have an extra-ventricular drain inserted into the ventricles to reduce the intracerebral pressure (ICP) and be admitted to the neurointensive care unit, where they are monitored closely. Patients will undergo an angiography to identify the (probable) aneurysm and afterward have the aneurysm coiled or clipped to prevent rebleeding4. Despite numerous trials of pharmacological therapies, only nimodipine, a calcium-channel antagonist, has shown to improve outcomes5. Multiple clinical trials are currently underway. Please see the review by Daou and colleagues for an extensive list6.
The rupture of an aneurysm has been described as the sudden onset of the worst headache ever experienced or a thunderclap headache. The rupture results in a steep rise in the ICP followed by a reduction in the cerebral blood flow (CBF). This reduction results in global ischemia of the brain, which can result in a loss of consciousness. This more mechanistic pathway, along with the initiated breakdown of the extravasated elements of blood, gives rise to cytokine release and activation of the innate immune system resulting in sterile neuroinflammation. Furthermore, breakdown of the blood-brain barrier, resulting in cerebral edema and disturbance in the ion homeostasis, is often observed. All these changes and more, coined early brain injury (EBI), occur within the first couple of days and results in neuronal loss and apoptosis7.
Approximately 1/3 of patients afflicted with aSAH will develop delayed cerebral ischemia (DCI) between day 4-148. DCI is defined as either the debut of a focal, neurological impairment or a drop of minimum two points on the Glasgow coma scale lasting for a minimum of 1 h, when other causes, including seizures and re-bleeding is excluded. DCI is associated with an increased risk of death and decreased functional outcome following aSAH9. Cerebral vasospasm (CVS), the narrowing of the cerebral arteries, has been known to be associated with DCI for decades and was formerly thought to be the sole reason for DCI. It has since been shown that CVS can occur without the development of DCI and more factors, including microvascular thrombosis and constriction, cortical spreading depression, and an inflammatory response of EBI have since been identified10,11,12.
Due to the large influence of EBI and DCI on the course of the disease and the outcome of the patients afflicted, animal models need to mimic these to the largest degree possible, while still being reproducible. Researchers have employed a wide range of different models in a variety of animals from mice to non-human primates to try and simulate aSAH. Sprague-Dawley and Wistar wildtype rats are currently the most commonly used laboratory animals, and the most common models are the endovascular perforation model, the cisterna-magna double injection model, and lastly the pre-chiasmatic single injection model, which will be described in this article13.
The pre-chiasmatic, single injection model was originally developed by Prunell and colleagues to counter some of the shortcomings of the other experimental models14. The surgery, when mastered, is highly reproducible and minimizes variation between animals. The model mimics SAH in humans on multiple points, including the sudden rise in ICP following the injection of blood, resulting in transient global ischemia due to a fall in the CBF15,16. It affects the anterior circulation, which is where most aSAH in humans occur17. The mortality ranges from 10%-33% depending on the study and amount of blood injected14,18. Delayed cell death and neuroinflammation can be detected on day 2 and 7 thereby providing variables to study the consequences of EBI and DCI19,20.
The study presents an updated description of the pre-chiasmatic single injection model in the rat along with a description of how to utilize the ICP-probe as a port for intrathecal administration of pharmaceutics.
This procedure is done in accordance with the European Union's Directive 2010/63/EU regarding the protection of animals used for scientific purposes and approved by the Danish Animal Experiments Inspectorate (license no. 2016-15-0201-00940). Surgery is performed using aseptic technique to the widest extent possible, including sterile instruments, gloves, catheters, and sutures. The study used male and female Sprague-Dawley rats weighing 230-350 g, group housed in 12-h light/dark cycle, with constant temperature of 22 °C (± 2 °C), and humidity of 55% (± 10%). The animals are provided with standard chow and water ad libitum. The animals are housed in single cages following surgery but can be returned to group caging when the ICP-probe has been removed. The anesthetic in this protocol is isoflurane gas but a 1.5 mL/kg of 3:2 intraperitoneal mixture of ketamine (100 mg/mL) and xylazine (20 mg/mL) is also effectful21.
1. Preparations
2. Anesthesia
3. Tail catheter
4. ICP probe
5. Placement of the needle and the Laser-Doppler probe
6. Induction of SAH
7. Recovery and awakening
8. ICP-probe removal (if not removed during surgery)
NOTE: Use a surgical microscope upon the surgeon's discretion.
Women have an increased risk of aSAH compared to men. Despite this, male rodents are primarily used in experiments due to possible bias from heterogeneity of estrus cycle in females. The representative results presented here are from a recent publication comparing female and male rats, confirming that the model produces similar results in female animals compared to male21. The study included 34 female Sprague-Dawley rats (18 SAHs and 16 shams). Shams did not have the spinal needle descended to the optic chiasm or blood injected. All other procedures were performed on Shams identical to SAHs. All the physiological parameters between groups were comparable. Lastly, a meta-analysis of data from previous experiments on the male rats was done and compared with the results of the present study21.
The rotating pole test is a test of gross sensorimotor function. The animal is placed on one end of a 150 cm by 45 mm pole, which can rotate up to 10 rpm. The goal is to reach the far end of the pole where a cage is placed. SAH rats did significantly worse on day 1 and 2, compared to sham animals on the rotating pole (Figure 1).
Following SAH, both the ET-1 and 5-HT receptor family are upregulated in the cerebral arteries resulting in an increased contraction when stimulated and thereby contributing to CVS22,23.The basilar artery (BA) and middle cerebral arteries (MCA) were removed following decapitation and used for myograph experiments. Both endothelin 1 (ET-1), an agonist for the ET-1 receptor family and 5-carboxamidotryptamine (5-CT), an agonist for the 5-HT-receptor family produced significantly increased vascular contraction in SAH compared to sham (Figure 2). Sensitivity can be observed by the lower concentrations needed to elicit contraction following SAH in both sexes.
Increased water content (edema) following SAH is a measure of reduced functional outcome in humans24. Significantly increased cerebral edema was found in SAH compared to sham on day 2. There was also a tendency toward increased edema in the hippocampus, but this was not statistically significant (p = 0.0508)21.
When comparing the above-mentioned data to historical male data, the results are comparable. The metadata shows increased contractility in male SAHs following addition of ET-1 or 5-CT (Figure 2). Furthermore, the SAH rats performed significantly worse compared to shams when doing the rotating pole test. The result indicated a decreased sensorimotor function (Figure 1).
Figure 5A shows the distribution of the autologous, injected blood following saline perfusion 30 min after induction of the SAH. The figure shows that the blood has been distributed in the subarachnoid space following pre-chiasmatic injection.
Figure 5B and Figure 5C shows the distribution of intrathecally injected dyes, followed by whole body saline perfusion for 30 min after the injection. Figure 5B shows the distribution of 25 µL of 20 mM Evans Blue (water soluble) and Figure 5C shows the distribution of 25 µL of 10 mM Oil Red O (water insoluble). Both dyes were found to be distributed in the subarachnoid space following the injection into the cisterna magna, confirming that this is a feasible model of intrathecal injection of both water soluble and insoluble compounds. Worth noticing is the formation of deposits around the arteries for the water insoluble compound.
Figure 1: Analysis of sensory-motor cognition in the first 2 days after SAH in male and female rats. Rotating pole test was performed on day 1 and day 2 after SAH. Rats of both genders had significant deficits compared to sham-operated rats of the same gender. Statistical differences in behavior between groups were tested by 2-way ANOVA on day 0, day 1, and day 2. Female no rotation and 3 rpm: p < 0.05. Female 10 rpm and all male data: p < 0.01. Values are means ± SEM. Republished with permission from Spray, S. et al.21. Please click here to view a larger version of this figure.
Figure 2: Analysis of increased sensitivity to ET-1 and 5-CT induced contractions in the basilar artery (BA) and middle cerebral artery (MCA) 2 days after SAH in male and female rats. (A,B) 60 mM K+-evoked (K+max) contractile responses were used as reference values for normalization of agonist-induced responses. The sensitivity to ET-1 was significantly increased 2 days after SAH compared to sham-operated rats of the same gender in both the BA and MCA. (C,D) The sensitivity to 5-CT was significantly increased 2 days after SAH compared to sham-operated rats of the same gender in both the BA and MCA. The concentration-response curves were statistically compared with two-way ANOVA. All data: p < 0.001. Values are means ± SEM. Republished with permission from Spray, S. et al.21. Please click here to view a larger version of this figure.
Figure 3: Overview of the setup before induction of SAH. From the top of the picture, note that the 1) injection needle, 2) laser-Doppler probe, and 3) the ICP probe are all in place. Please click here to view a larger version of this figure.
Figure 4: Sample trace following intrathecal injection. The red graph shows the blood pressure in mmHg. The blue graph shows the ICP in mmHg and the green graph shows the CBF in the arbitrary unit FU. The spike in ICP is the result of blood injection. Notice that this results in a drop in the CBF > 50% of baseline for more than 5 min. The ICP rise furthermore results in a small rise in blood pressure which normalizes within seconds. Please click here to view a larger version of this figure.
Figure 5: Distribution of intrathecally injected blood and colored dyes. (A) Distribution of autologous blood 30 min after SAH induction. (B) Distribution of 25 µL of 20 mM Evans Blue following intrathecal injection through ICP-catheter. (C) Distribution of 25 µL of 10 mM Oil Red O following intrathecal injection through ICP-catheter. All animals were anesthetized with intraperitoneal ketamine/xylazine mixture followed by saline perfusion. Please click here to view a larger version of this figure.
The pre-chiasmatic single injection model of SAH mimics several important elements of human SAH, including the spike in ICP, reduction of CBF, transient global ischemia, upregulation of neuroinflammatory markers, and CVS14,15,16,18,19,20. The ICP-probe was also used as a port for intrathecal administration (Figure 5). Furthermore, the study shows that the model performs similarly in male and female animals21. The model does not include the development of and the subsequent rupture of an aneurysm. A range of models have attempted to produce SAH from a ruptured aneurysm by induction of systemic hypertension either surgically or pharmacologically and by weakening the arterial wall using elastase25,26,27. All attempts have produced aneurysmal SAH in a subset of animals, but these models have an inherent variability including the inability to predict when the aneurysm will rupture. The models are not very suitable for pre-clinical research on SAH18,28.
Among other murine, SAH models, the endovascular perforation model includes the rupture of a vessel, somewhat mimicking the rupture of an aneurysm, but prone to high variability and mortality. The model described here is better traceable and more reproducible as the blood volume is pre-determined and injection pressure can be controlled. The double injection model has a higher probability of producing delayed CVS, but primarily affects the posterior circulation and includes an unphysiological second blood injection. In comparison, this model resembles SAH in humans as it is a single injection of the anterior circulation and it produces a reproducible ICP rise18.
The influence of different anesthesia regimes on experimental SAH is unclear and the experimental data is contradictory. One study reported possible inhibition of cytokines and general neuroinflammation in an endovascular perforation model in mice when using isoflurane inhalations29. Another rodent model resulted in reduced respiratory parameters and increased brain edema along with reduced regional CBF when using isofluranes30. However, a meta-analysis comparing mortality in mouse models showed no difference in mortality between isoflurane and other types of anesthesia31. In agreement, the above protocol has successfully used either isoflurane inhalation or an intraperitoneal ketamine/xylazine mixture with similar results in both groups21.
To ensure high reproducibility and proper data acquisition, overall emphasis is on the steps regarding placement of the monitoring equipment. Correct placement of the tail catheter facilitates continuous monitoring of blood pressure and the ability to do blood gas analyses. Proper placement of the ICP catheter ensures correct ICP monitoring and the subsequent possibility of intrathecal intervention. Appropriate placement of the Laser-Doppler probe ensures that the reduction of CBF can be monitored, where a reduction of 50% or lower of baseline score for at least 5 min following SAH induction ensures a strong ischemia32. By ensuring that all monitoring steps are in order, the researcher can secure correct data collection following the SAH induction.
The protocol describes the pre-chiasmatic single injection model of subarachnoid hemorrhage with updates and modification. The model has been valuable for SAH-research and will probably continue to contribute toward a better understanding of subarachnoid hemorrhage, including early brain injury and delayed cerebral ischemia.
The authors have nothing to disclose.
The work was supported by the Lundbeck Foundation and the Lundbeck Grant of Excellence (no. R59-A5404). Funders had no role in any part of the manuscript.
16 G peripheral vein catheter | BD Venflon | 393229 | Needle shortened, distal 1 cm curved. Wings removed |
Anesthesia bell/ chamber | Unknown | ||
Blood gas analyzer | Radiometer | ABL80 | |
Blood pressure (BP) monitor | Adinstruments | ML117 | Connects to Powerlab |
Curved forceps, 12 cm x 3 | F.S.T | 11001-12 | For anesthesia |
Cylindrical pillow, 28 cm x 4 cm | Homemade | Made from surgical towels | |
Data acquisition hardware | Adinstruments | ML870 Powerlab | |
Data acquistion software | Adinstruments | LabChart 6.0 | |
Drill | KMD | 1189 | |
Drill controller | Silfradent | 300 IN | |
Flexible light | Schott | KL200 | |
Heating pad | Minco | 1135 | |
Hypodermic needle, 20 G | KD Medical | 301300 | Connects to stereotaxic frame |
ICP monitor | Adinstruments | ML117 | Connects to Powerlab |
Isoflurane vaporizer | Ohmeda | TEC3 | |
Laptop | Lenovo | T410 | |
Laser doppler monitor | Adinstruments | ML191 | |
Laser doppler probe | Oxford Optronics | MSF100XP | Connects to laser doppler monitor |
Needle holder, 13 cm | F.S.T | 12001-13 | For anesthesia |
Precision syringe, 0.025 mL | Hamilton | 547407 | |
Stereotaxic frame | Kopf Instruments | M900 | |
Surgical microscope | Carl Zeiss | F170 | |
Suture needle | Allgaier | 1245 | For anesthesia |
Temperaure controller | CWE,INC. | TC-1000 | |
Transducer x 2 | Adinstruments | MLT0699 | Connects to BP and ICP monitor |
Ventilator | Ugo Basile | 7025 | |
Veterinary clipper | Aesculap | GT421 | |
3-pronged Blair retractor, 13.5 cm | Agnthos | 17022–13 | |
Blunt Alm retractor | F.S.T | 17008-07 | |
Curved forceps, 12 cm x 2 | F.S.T | 11001-12 | |
Needle holder, 13 cm | F.S.T | 12001-13 | |
Straight Dumont forceps, 11 cm | F.S.T | 11252-00 | |
Straight Halsted-Mosquito hemostat x 2 | F.S.T | 13008-12 | |
Straight Iris scissor, 9 cm | F.S.T | 14090-09 | |
Straight Vannas scissor, 10.5 cm | F.S.T | 15018-10 | |
Absorpable swabs | Kettenbach | 31603 | |
Black silk thread, 4-0, 5 x 15 cm | Vömel | 14757 | |
Bone wax | Aesculap | 1029754 | |
Carbomer eye gel 2 mg/g | Paranova | ||
Cotton swab | Heinz Herenz | WA-1 | |
Cotton tipped applicator x 4 | Selefa | 120788 | |
Hypodermic needle, 23 G x2 | KD Medical | 900284 | Connects to stopcock. Remove distal end |
Hypodermic needle, 23 G x3 | KD Medical | 900284 | Remove distal end. 2 connects to stopcock, 1 to syringe |
ICP probe: | Homemade | Made of the following: | |
Polythene tubing, 20 mm | Smiths medical | 800/100/200 | Inner diameter (ID): 0.58 mm, Outer diameter (OD): 0.96 mm. |
Silicone tubing, 10 mm | Fisher | 15202710 | ID: 0.76 mm, OD: 2.4 mm. |
Silicone tubing, 2 mm | Fisher | 11716513 | ID: 1.0 mm, OD: 3.0 mm. |
Micro hematocrit tubes | Brand | 7493 11 | |
OP-towel, 45 cm x75 cm | Mölnlycke | 800430 | |
PinPort adapter, 22 G | Instech | PNP3F22 | |
PinPort injector | Instech | PNP3M | |
Polythene tubing, 2 x 20 cm | Smiths medical | 800/100/200 | Connects to syringe. ID: 0.58 mm, OD: 0.96 mm. |
Rubberband | Unknown | ||
Scalpel, 10 blade | Kiato | 23110 | |
Spinalneedle, 25 G x 3.5'' | Braun | 5405905-01 | |
Stopcock system, Discofix x 2 | Braun | 16494C | Connects to transducer |
Suture, 4-0, monofil, non-resorbable x 3 | Ethicon | EH7145H | |
Syringe, 1 mL | BD Plastipak | 1710023 | |
Syringe, luer-lock, 10 mL x 4 | BD Plastipak | 305959 | Connects to transducer |
Tissue adhesive glue | 3M | 1469SB | |
0.5% Chlorhexidine spirit | Faaborg Pharma | 210918 | |
Carprofen 50 mg/mL | ScanVet | 43715 | Diluted 1:10 |
Isoflurane | Baxter | ||
Isotonic saline | Amgros | 16404 | |
Lidocaine-Adrenaline 10 mg/5 µg/mL | Amgros | 16318 |